ASH 2024 Highlights for Myeloproliferative Neoplasm (MPN) Patients with Claire Harrison, MD
SpotifyIn this HealthTree for Myelofibrosis Podcast episode, we were fortunate enough to speak with Professor Claire Harrison about highlights from the ASH 2024 conference, which was held in December 2024. This is the largest hematology conference in the world, and people from all over the world travel to the event to hear about and share the latest in hematology.
Dalton Bean
Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Claire Harrison, MD, FRCP, FRCPath
Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy chief medical officer. The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. Her work has led to the approval of new therapies such a ruxolitinib, fedratinib, momelotinib and pacritinib. In the past 10 years she has published widely (>300 academic articles). In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.
